LEXINGTON, Mass. , June 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced the pricing of an underwritten public [...]
LEXINGTON, Mass. , June 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that it intends to sell, subject to market [...]
- Top-Line Data from Study of Approximately 350 Patients Expected in Q4 2020 - - Second Clinical Study Expected to Initiate Shortly with Similar Design and Additional Microbiome Analysis - LEXINGTON, Mass. , May 14, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, [...]
- Initiating Clinical Studies of KB109 in Outpatients with Mild-to-Moderate COVID-19; Data Anticipated in Q4 2020 - - Expanding Work in Immune-Mediated and Inflammatory Diseases; Data from New Clinical Study in Ulcerative Colitis Expected in Mid-2021 - - Conference Call Scheduled for 8:30 [...]
LEXINGTON, Mass. , May 12, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced that it plans to release first [...]
Mike Bonney, former CEO of Cubist Pharmaceuticals, to lead Kaleido through its next phase of growth $65 million in funds raised since its founding in 2015 Funds to advance Kaleido's robust pipeline of novel microbiome therapies BEDFORD, Mass., Sept. 18, 2017 /PRNewswire/ — Kaleido Biosciences, [...]
- Agreement will increase productivity and speed of Kaleido’s clinical development programs BEDFORD, Mass. –( BUSINESS WIRE )– Kaleido Biosciences, a clinical-stage biotechnology company developing novel chemistries to unlock the power of the human microbiome, today announced an agreement [...]
Biopharmaceutical veterans John W. Davies, Ph.D. and Michael D. Bruce, Ph.D. to join executive team BEDFORD, Mass. –( BUSINESS WIRE )– Kaleido Biosciences, a clinical-stage biotechnology company developing novel chemistries to unlock the power of the human microbiome, announced today [...]
BEDFORD, Mass . –( BUSINESS WIRE )– Kaleido Biosciences , a clinical-stage biotechnology company developing novel chemistries to unlock the power of the human microbiome, today announced the appointment of Alison Lawton as president and chief operating officer. [...]
BEDFORD, Mass. –( BUSINESS WIRE )– Kaleido Biosciences , a clinical-stage biotechnology company developing novel chemistries to unlock the power of the human microbiome, today announced the appointment of Wendy Arnold as senior vice president of human resources. [...]